Illumina, Inc. $ILMN Shares Bought by Bourgeon Capital Management LLC

Key Points

• Bourgeon Capital Management LLC increased its stake in Illumina, Inc. by 76.4% during the second quarter, acquiring an additional 61,468 shares, which makes Illumina the firm's 7th largest position.
• Illumina reported earnings of $1.19 per share for the most recent quarter, surpassing analyst expectations of $1.02, despite a 4.8% decline in revenue year-over-year.
• Wall Street analysts have generally rated Illumina as a Hold with an average target price of $123.06, although recent price targets from firms like Barclays and Morgan Stanley suggest moderate growth expectations.

Bourgeon Capital Management LLC raised its stake in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 76.4% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 141,896 shares of the life sciences company's stock after acquiring an additional 61,468 shares during the period. Illumina accounts for approximately 2.7% of Bourgeon Capital Management LLC's portfolio, making the stock its 7th largest position. Bourgeon Capital Management LLC owned approximately 0.09% of Illumina worth $13,538,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the stock. Moors & Cabot Inc. boosted its stake in Illumina by 2.5% in the first quarter. Moors & Cabot Inc. now owns 5,855 shares of the life sciences company's stock valued at $465,000 after acquiring an additional 145 shares in the last quarter. Tokio Marine Asset Management Co. Ltd. boosted its stake in Illumina by 3.0% in the first quarter. Tokio Marine Asset Management Co. Ltd. now owns 5,604 shares of the life sciences company's stock valued at $445,000 after acquiring an additional 164 shares in the last quarter. Nissay Asset Management Corp Japan ADV boosted its stake in Illumina by 0.9% in the first quarter. Nissay Asset Management Corp Japan ADV now owns 22,362 shares of the life sciences company's stock valued at $1,774,000 after acquiring an additional 207 shares in the last quarter. Rise Advisors LLC raised its holdings in shares of Illumina by 173.6% in the first quarter. Rise Advisors LLC now owns 353 shares of the life sciences company's stock valued at $28,000 after buying an additional 224 shares during the last quarter. Finally, Farther Finance Advisors LLC raised its holdings in shares of Illumina by 9.8% in the second quarter. Farther Finance Advisors LLC now owns 2,521 shares of the life sciences company's stock valued at $241,000 after buying an additional 225 shares during the last quarter. Institutional investors and hedge funds own 89.42% of the company's stock.

Wall Street Analysts Forecast Growth

ILMN has been the subject of a number of research reports. Barclays upped their target price on shares of Illumina from $85.00 to $90.00 and gave the company an "underweight" rating in a report on Friday, August 1st. Morgan Stanley upped their target price on shares of Illumina from $100.00 to $105.00 and gave the company an "equal weight" rating in a report on Monday, August 4th. Canaccord Genuity Group upped their target price on shares of Illumina from $99.00 to $105.00 and gave the company a "hold" rating in a report on Friday, August 1st. Evercore ISI upped their target price on shares of Illumina from $116.00 to $128.00 and gave the company an "outperform" rating in a report on Tuesday, July 8th. Finally, Scotiabank cut shares of Illumina from a "sector outperform" rating to a "sector perform" rating and set a $125.00 target price for the company. in a report on Friday, July 11th. Six research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, Illumina has an average rating of "Hold" and an average target price of $123.06.

Illumina Trading Up 0.2%

Shares of ILMN opened at $91.87 on Tuesday. The company has a current ratio of 1.81, a quick ratio of 1.41 and a debt-to-equity ratio of 0.66. The firm's 50-day moving average is $99.57 and its two-hundred day moving average is $89.51. Illumina, Inc. has a twelve month low of $68.70 and a twelve month high of $156.66. The firm has a market capitalization of $14.12 billion, a P/E ratio of 11.63, a PEG ratio of 2.21 and a beta of 1.43.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its earnings results on Thursday, July 31st. The life sciences company reported $1.19 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.17. Illumina had a net margin of 29.36% and a return on equity of 28.93%. The company had revenue of $1.06 billion for the quarter, compared to analyst estimates of $1.12 billion. During the same period in the prior year, the business posted $0.36 earnings per share. The firm's revenue for the quarter was down 4.8% compared to the same quarter last year. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. On average, research analysts predict that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.